The OlympiA trial demonstrated a 9% difference in 3-year invasive disease-free survival (iDFS) in favor of 1 year of adjuvant olaparib vs placebo in patients with high risk HER2-negative and gBRCA1/2-positive BC who had completed standard chemotherapy. The gene discussed is ERBB2; the disease is breast cancer.